首页 | 本学科首页   官方微博 | 高级检索  
     

急性心肌梗死患者PCI延时与无延时应用比伐芦定的对照研究
引用本文:李雪冬,胡业梅,王真,吴纲,李君,武永元,商卓. 急性心肌梗死患者PCI延时与无延时应用比伐芦定的对照研究[J]. 中华全科医学, 2022, 20(8): 1323-1327. DOI: 10.16766/j.cnki.issn.1674-4152.002587
作者姓名:李雪冬  胡业梅  王真  吴纲  李君  武永元  商卓
作者单位:蚌埠市第二人民医院心血管内科,安徽 蚌埠 233000
基金项目:安徽省卫生健康委科研项目AHWJ2021b095蚌埠市科技创新指导类项目20190338
摘    要:目的 评价急性心肌梗死(AMI)患者接受经皮冠状动脉介入治疗(PCI)时无延时比伐芦定联合仅冠脉内替罗非班方案的疗效和安全性。方法 选取2020年4月—2021年3月蚌埠市第二人民医院心内科收治的150例AMI患者,采用随机数字表法随机分为2组:试验组(无延时组,75例)和对照组(延时组,75例)。观察2组患者术后TIMI血流分级(TFG)及校正的TIMI血流帧数计数(cTFC),术后90 min心电图ST段回落(STR)情况,术后第7天心功能指标,术后30 d内所有出血事件及术后30 d主要不良心血管事件(MACE)。结果 2组TFG、cTFC、术后90 min心电图STR(Z=0.524,P=0.770)、MACE(1.3%vs. 0,P=0.999)、左心室射血分数[(49.5±6.6) vs.(50.6±5.7),t=-1.092,P=0.276]、左心室舒张末期内径[(50.0±8.9) mm vs.(51.2±7.6) mm,t=-0.888,P=0.376]及室壁运动异常(86.7%vs. 90.1%,χ2=0.597,P=0.440)比较,差异均无...

关 键 词:比伐芦定  替罗非班  经皮冠状动脉介入治疗  急性心肌梗死
收稿时间:2022-02-22

Randomised controlled trial of delayed versus undelayed bivalirudin in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention
Affiliation:Department of Cardiovascular Medicine, the Second People's Hospital of Bengbu, Bengbu, Anhui 233000, China
Abstract:  Objective  To evaluate the efficacy and safety of undelayed bivalirudin combined with intracoronary tirofiban only during primary percutaneous coronary intervention (PCI) in patients with acute elevation myocardial infarction (AMI).  Methods  A total of 150 patients with AMI admitted to the Department of Cardiology, Bengbu Second People's Hospital from April 2020 to March 2021 were selected and randomly divided into two groups: the experimental group (n=75) and the control group (n=75). Postoperative TIMI flow grade (TFG), corrected TIMI frame count(cTFC), 90 min postoperative ST segment resolution (STR), postoperative cardiac function parameters, any bleeding events and major adverse cardiovascular events (MACEs) after 30 days were recorded and analysed after completion of primary PCI.  Results  No significant differences between the two groups were found in terms of the TFG, cTFC, STR (Z=0.524, P=0.770), MACE (1.3% vs. 0, P=0.999), left ventricular ejection fraction [(49.5±6.6)% vs. (50.6±5.7) %, t=-1.092, P=0.276], left ventricular end-diastolic dimension [(50.0±8.9) mm vs. (51.2±7.6) mm, t=-0.888, P=0.376] and regional wall motion abnormality (86.7% vs. 90.1%, χ2=0.597, P=0.440). The bleeding events in the experimental group were significantly less than those in the control group, and the difference was statistically significant (5.3% vs. 18.7%, χ2=6.221, P=0.035).  Conclusion  The undelayed bivalirudin combined with intracoronary tirofiban only strategy, which is associated with good safety demonstrated by reduced bleeding events, is an alternative regimen for patients with AMI undergoing primary PCI. 
Keywords:
点击此处可从《中华全科医学》浏览原始摘要信息
点击此处可从《中华全科医学》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号